Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease

V2, Crosslink

🧫

Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-senolyti

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease ## Background and Rationale This Phase IIa clinical trial evaluates the therapeutic potential of senolytic therapy using dasatinib plus quercetin (D+Q) in early Alzheimer's disease patients, targeting the senescence-associated secretory phenotype (SASP) that contributes to neuroinflammation and cognitive decline. Cellular senescence accumulates in the aging brain and is accelerated in AD, with senescent cells secreting pro-in

METHODOLOGY NOTES

**Phase 1: Screening and Baseline Assessment (Weeks -4 to 0)** • Screen 200 potential participants aged 60-85 with mild cognitive impairment or early AD (CDR 0.5-1.0) • Confirm amyloid positivity via PET imaging (Centiloid >20) or CSF Aβ42/40 ratio <0.067 • Obtain comprehensive neuropsychological battery (ADAS-Cog, MMSE, CDR-SB, FAQ) • Collect baseline blood biomarkers: p16INK4a, p21, IL-6, TNF-α, SASP factors • Perform baseline brain MRI with volumetric analysis and DTI sequences • Lumbar puncture for CSF collection: Aβ40, Aβ42, tau, p-tau181, neurofilament light • Randomize 120 eligible participants 1:1 to D+Q vs placebo arms (n=60 each) **Phase 2: Treatment Period (Weeks 1-24)** • Administer dasatinib 100mg + quercetin 1000mg orally for 2 consecutive days every 4 weeks (6 cycles total) • Placebo group receives matched capsules on same schedule • Safety monitoring every 2 weeks: CBC, comprehensive metabolic panel, liver enzymes • Cognitive assessments at weeks 4, 8, 12, 18, and 24 •

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.907032Z'}
summary	# Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease ## Background and Rationale This Phase IIa clinical trial evaluates the therapeutic potential of senolytic therapy using dasatini
entities	{'genes': ['SASP'], 'diseases': ["Alzheimer's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Change from baseline in cerebrospinal fluid SASP inflammatory markers (IL-6, TNF-α, IL-1β composite score) at 12 months in patients receiving D+Q versus placebo.
methodology_notes	Phase 1: Screening and Baseline Assessment (Weeks -4 to 0) • Screen 200 potential participants aged 60-85 with mild cognitive impairment or early AD (CDR 0.5-1.0) • Confirm amyloid positivity via
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.907038', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

591

Outgoing

498

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease

derives from (16)

supports (5)

💬 Discussion